This review examines engineered combination nanomedicine strategies to combat drug resistance in cancer, suggesting innovative approaches.
This review examines engineered combination nanomedicine strategies that integrate co-delivery platforms, tumor microenvironment targeting, and predictive translational models to overcome cancer drug resistance.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: